drugset / Trial / NCT05292040

A Study of LY3857210 in Healthy Participants

NCT05292040

Phase 1 Completed 10 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.

Timeline

Start
2022-03-17
Primary completion
2022-12-14
Completion
2022-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3857210 Unknown Oral

Indications

No indication recorded.